Franklin Covey Added to Focus List and 3 Stock Analyses Not to Miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) target has been lowered by Roth Capital following the company’s CPP-109 to treat cocaine addiction failed in a clinical trial. The firm continues to believe that the company’s other products possess greater potential than CPP-109, and it keeps its Buy rating on the stock.

Franklin Covey Co. (NYSE:FC) has been added to Roth Capital’s Focus List after it reported stronger Q4 results than predicted. The firm keeps its Buy rating but raised its target to $18.50 from $17 on the stock.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Weatherford International Ltd. (NYSE:WFT) is expected by Barclays to give a new detailed financial strategy on the conference call, and it recommends purchasing the shares on weakness. Shares have an Overweight rating and a $18 price target.

F5 Networks, Inc. (NASDAQ:FFIV)  iRules and iApp are believed by Pacific Crest to give the company’s products “unmatched programmability.” The firm recommends purchasing the shares after they fell 35 percent from peak levels.

Don’t Miss: Clovis Oncology: This Treatment is Out of Reach.